Title : Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.

Pub. Date : 2006 Oct 1

PMID : 17020995






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Combined treatment of cultured human CML and BaF3 cells with vorinostat and dasatinib induced more apoptosis than either agent alone, as well as synergistically induced loss of clonogenic survival, which was associated with greater depletion of Bcr-Abl, p-CrkL, and p-STAT5 levels. Vorinostat ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 Cotreatment with dasatinib and vorinostat also attenuated the levels of Bcr-AblE255K and Bcr-AblT315I and induced apoptosis of BaF3 cells with ectopic expression of the mutant forms of Bcr-Abl. Vorinostat ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
3 Finally, cotreatment of the primary CML cells with vorinostat and dasatinib induced more loss of cell viability and depleted Bcr-Abl or Bcr-AblT315I, p-STAT5, and p-CrkL levels than either agent alone. Vorinostat ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens